A Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of Danicopan After Administration as an Oral Tablet in the Fed and Fasted States in Participants of Japanese Descent
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Number Of Participants With Treatment-Emergent Adverse Events
研究概览
简要总结
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of danicopan after a single-dose oral administration under fed and fasting conditions to participants of Japanese descent.
详细描述
This will be an open-label, randomized, single-dose, 3-period, 3-treatment crossover study in participants of Japanese descent.
On Day 1 of each period, participants will receive a single oral dose of 200 milligrams (mg) danicopan under fasting conditions, 200 mg danicopan under fed conditions, or 400 mg danicopan under fed conditions. Participants will receive each treatment once, according to the randomization schedule. There will be a washout period of at least 7 days between each dose of study intervention.
Safety will be assessed throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants who are of Japanese descent defined as:
- •First generation (born to 2 Japanese parents and 4 Japanese grandparents)
- •Born in Japan, and not have lived outside Japan for greater than 10 years
- •Lifestyle, including diet, must not have significantly changed since leaving Japan
- •No clinically significant history or presence of electrocardiogram findings as judged by the Investigator at screening and prior to the first dose of study intervention in Period
- •Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meters squared, inclusive, with a minimum body weight of 50.0 kg at screening.
排除标准
- •Evidence of any clinically significant deviation from normal in clinical laboratory evaluations, as determined by the Investigator or designee.
- •History of any medical or psychiatric condition or disease that, in the opinion of the Investigator or designee, might limit the participant's ability to complete or participate in this clinical study, confound the results of the study, or pose an additional risk to the participant by their participation in the study.
- •History or presence of clinically significant hypersensitivity or idiosyncratic reaction to the study interventions or related compounds or commonly used antibacterial agents.
- •History of meningococcal infection, or a first-degree relative with a history of meningococcal infection.
- •History of febrile illness, or other evidence of infection, within 14 days prior to the first dose of study intervention.
- •Any major surgery within 4 weeks of the first dose of study intervention.
- •Diagnosis or history of Gilbert's syndrome, in the opinion of the Investigator or designee.
- •Unable to refrain from or anticipates the use of any drug.
- •Receipt of a vaccine within 30 days prior to the first dose of study intervention.
- •Receipt of blood products within 6 months prior to the first dose of study intervention.
- •Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days prior to the first dose of study intervention, whichever is longer.
- •Seated blood pressure is less than 90/40 millimeters of mercury (mmHg) or greater than 140/90 mmHg at screening.
- •Participants who test positive for human immunodeficiency virus, hepatitis B virus, and/or hepatitis C virus.
- •Current tobacco users and smokers or a positive cotinine test at screening.
- •Donation of whole blood from 3 months prior to the first dose of study intervention, or of plasma from 30 days prior to the first dose of study intervention.
- •Positive drugs of abuse screen at screening or Day -1 of Period
- •Positive results for alcohol screen at screening or Day -1 of Period
- •Is a female with a positive pregnancy test at screening or Day -1 of Period 1 or who is lactating, or who plan to become pregnant (within 5 months of screening).
研究组 & 干预措施
Danicopan 400 mg Fed
Fed participants will receive a single dose of 400 mg danicopan.
干预措施: Danicopan (Drug)
Danicopan 200 mg Fasted
Fasting participants will receive a single dose of 200 mg danicopan.
干预措施: Danicopan (Drug)
Danicopan 200 mg Fed
Fed participants will receive a single dose of 200 mg danicopan.
干预措施: Danicopan (Drug)
结局指标
主要结局
Number Of Participants With Treatment-Emergent Adverse Events
时间窗: Day 1 (after first dose) through safety follow-up (10 +/- 2 days after last dose)
Time To Maximum Observed Concentration (Tmax) Of Danicopan In Both Fed And Fasted States
时间窗: up to 72 hours postdose
Dose Proportionality Of Danicopan In Fed State Assessed by AUC
时间窗: up to 72 hours postdose
Area Under The Concentration Versus Time Curve (AUC) Of Danicopan In Both Fed And Fasted States
时间窗: up to 72 hours postdose
Maximum Observed Concentration (Cmax) Of Danicopan In Both Fed And Fasted States
时间窗: up to 72 hours postdose
Dose Proportionality Of Danicopan In Fed State Assessed by Cmax
时间窗: up to 72 hours postdose
次要结局
- Activity Of Danicopan As Measured By Alternative Pathway Wieslab Assay(up to 72 hours postdose)
- Complement Factor B Fraction b Levels(up to 72 hours postdose)